Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort study

[1] Colilla S(2013)Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population Am J Cardiol 112 1142-1147

[2] Crow A(2009)Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation Circ Cardiovasc Imaging 2 100-106

[3] Petkun W(2011)Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography PLoS One 6 e24964-99

[4] Singer DE(2019)Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review J Am Coll Cardiol 74 83-436

[5] Simon T(2019)Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting Ther Adv Cardiovasc Dis 13 1753944719891688-254

[6] Liu X(2019)Antithrombotic Agents Circ Res 124 426-790

[7] Nucifora G(2018)2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS Eur Heart J 39 213-1912

[8] Schuijf JD(2018)2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome J Formos Med Assoc 117 766-2070

[9] Tops LF(2006)Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 1903-168

[10] Kralev S(2010)Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents Circulation 121 2067-2434

[1] Colilla S(2013)Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population Am J Cardiol 112 1142-1147

[2] Crow A(2009)Prevalence of coronary artery disease assessed by multislice computed tomography coronary angiography in patients with paroxysmal or persistent atrial fibrillation Circ Cardiovasc Imaging 2 100-106

[3] Petkun W(2011)Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography PLoS One 6 e24964-99

[4] Singer DE(2019)Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review J Am Coll Cardiol 74 83-436

[5] Simon T(2019)Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting Ther Adv Cardiovasc Dis 13 1753944719891688-254

[6] Liu X(2019)Antithrombotic Agents Circ Res 124 426-790

[7] Nucifora G(2018)2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS Eur Heart J 39 213-1912

[8] Schuijf JD(2018)2018 Guidelines of the Taiwan Society of Cardiology, Taiwan Society of Emergency Medicine and Taiwan Society of Cardiovascular Interventions for the management of non ST-segment elevation acute coronary syndrome J Formos Med Assoc 117 766-2070

[9] Tops LF(2006)Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 1903-168

[10] Kralev S(2010)Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents Circulation 121 2067-2434